Market research
AT2.F Atara Biotherapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 33.38
- Dividend yield
- Not available
- Beta
- 0.53
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0465131078
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 33.38
- Dividend yield
- Not available
- Beta
- 0.53
About
About Atara Biotherapeutics, Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AT2.F discussion.
5 years, 5 months ago
Atara Biotherapeutics, Inc is currently in a long term downtrend where the price is trading 13.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Atara Biotherapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 3.6% to $-81M since the same quarter in the previous year.
Finally, its free cash flow grew by 92.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Atara Biotherapeutics, Inc gets an overall score of 2/5.